NEW Capital Fund
VC Fund
Little Chute, United States
NEW Capital Fund is a Wisconsin-based private equity fund focused on life sciences, IT, agriculture, and manufacturing sectors.
- Total investments:
- 17
- Last investment:
- Lead investor:
- 12%
Last updated:
For AI agents: llms.txt
Industries NEW Capital Fund invests in
BiotechnologyMedicalHealth CareLife ScienceNanotechnology
Stages NEW Capital Fund invests in
Funding RoundDebt FinancingSeries A
Countries NEW Capital Fund invests in
United States
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Charlie Goff
|
|||
|
David Gitter
|
|||
Robert DeBruin
|
|||
|
Steve Predayna
|
|||
Investment Focus
Industry
- Biotechnology 4 (24%)
- Medical 3 (18%)
- Health Care 2 (12%)
- Life Science 2 (12%)
- Nanotechnology 2 (12%)
Stage
- Funding Round 7 (41%)
- Debt Financing 2 (12%)
- Series A 1 (6%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Charlie Goff
Accounts
|
Accounts | Total investments: 0 | Find email | |
|
David Gitter
MD
|
MD | Total investments: 0 | Find email | |
|
Robert DeBruin
President
|
President | Total investments: 0 | Find email | |
|
Steve Predayna
Vice President
|
Vice President | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Rapid Diagnostek
|
Rapid Diagnostek formerly Intellignostics, has developed a patented, inexpensive, easy to use sensor appropriate for detecting bacteria, viruses, spores and disease biomarkers. Markets of opportunity include human and veterinary diagnostic, environmental, biohazard, bioterrorism, agricultural commodity, and food safety testing. Its technologyoffers remarkably faster and less expensive results than existing methods. Current diagnostic tests can take hours to days from the time a sample is taken to delivery of results. Rapid Diagnostek's IntelliProbe Immunosensor (IPI) platform can deliver results at the point of sampling in under 60 seconds. The sensor has performed as intended in the laboratory and the company is now developing a fully functioning device and initial assays to aggressively move towards commercialization. | Jan 01, 2019 | |
Invenra
|
Invenra is focused on discovering the next generation of best-in-class biologics, with an emphasis on antibodies and their derivatives. The company's proprietary technology combines the cell-free expression of full-length antibodies and extreme miniaturization, enabling the screening of unprecedented numbers of full-length antibodies inphenotypic assays. Invenra touts a broad scientific foundation and a team of scientists with deep expertise in key areas ranging from genomics to biochemistry to bioengineering. Their background is well balanced between cutting edge basic research and commercial products and services.The company was established in 2011 and is based in Madison, Wisconsin, United States. | $2.9M / Oct 03, 2017 | |
Swallow Solutions
|
The Swallow Solutions website offers help to those with swallowing difficulties, also called dysphagia. There are two parts to dysphagia: diagnostic and treatment devices for swallowing problems, and nutritional food products tailored to a patient's diagnosed level of swallowing difficulty. | $156.5K / Debt Financing / Sep 13, 2016 | |
|
Invenra
|
Invenra is focused on discovering the next generation of best-in-class biologics, with an emphasis on antibodies and their derivatives. The company's proprietary technology combines the cell-free expression of full-length antibodies and extreme miniaturization, enabling the screening of unprecedented numbers of full-length antibodies inphenotypic assays. Invenra touts a broad scientific foundation and a team of scientists with deep expertise in key areas ranging from genomics to biochemistry to bioengineering. Their background is well balanced between cutting edge basic research and commercial products and services.The company was established in 2011 and is based in Madison, Wisconsin, United States. | $3M / Jul 20, 2016 | |
|
Invenra
|
Invenra is focused on discovering the next generation of best-in-class biologics, with an emphasis on antibodies and their derivatives. The company's proprietary technology combines the cell-free expression of full-length antibodies and extreme miniaturization, enabling the screening of unprecedented numbers of full-length antibodies inphenotypic assays. Invenra touts a broad scientific foundation and a team of scientists with deep expertise in key areas ranging from genomics to biochemistry to bioengineering. Their background is well balanced between cutting edge basic research and commercial products and services.The company was established in 2011 and is based in Madison, Wisconsin, United States. | $4M / May 24, 2016 | |
|
Swallow Solutions
|
The Swallow Solutions website offers help to those with swallowing difficulties, also called dysphagia. There are two parts to dysphagia: diagnostic and treatment devices for swallowing problems, and nutritional food products tailored to a patient's diagnosed level of swallowing difficulty. | $1.1M / Mar 17, 2015 | |
Silatronix
|
Silatronix develops organosilicon electrolytes for energy storage devices such as ultracapacitors and lithium-ion batteries. The company's technology combines Dr. West's expertise in organosilicon compounds with that of Dr. Hamers in nanostructured electrodes and electronic properties of materials. It was founded in 2007 andheadquartered in Wisconsin, United States. | $2.1M / Jan 01, 2015 | |
MyAlerts
|
MyAlerts (formerly TrackIf) is a Customer Engagement Platform that allows site users to subscribe to personal alerts on nearly any page of their website based on changes or trigger events that they want. This provides customer-driven marketing that performs 5x to 10x better than mass marketing online.They work with some of the top retailers,travel, classifieds, and news sites to help drive their users back 5x to 10x more by letting them self-personalize the updates they want on their sites, such as price alerts, new item alerts, product availability alerts, review alerts, customer support alerts, and more.Instead of investing millions into personalization technology, MyAlerts is a cloud-based solution that let's sites turn on user-personalized alerting nearly instantly with dramatic results.Similar to how DVR's changed TV viewing by allowing users to "tune in" to what they want, when they want, MyAlerts allows your users to do the same thing which drives 100% relevant updates to them which will increase repeat visits and give you visibility to your users demand and future purchase intent. | $2.9M / Debt Financing / Apr 03, 2014 | |
Hopster
|
Hopster is a digital experience that helps CPG Brands convert coupons into relationships that drive engagement, loyalty, targeted trial, cross-selling and advocacy.They help Consumer Packaged Goods (CPG) brands:-Deliver targeted and personalized promotions for proven engagement-Link digital advertising to in-store sales-Capturehousehold-level buying dataHopster’s flagship site - Hopster.com - is a fun, interactive consumer website that allows shoppers to maximize their savings with personalized coupon offers and relevant branded content in an experience that is part game and part coupons. | $325K / Jan 01, 2014 | |
|
Swallow Solutions
|
The Swallow Solutions website offers help to those with swallowing difficulties, also called dysphagia. There are two parts to dysphagia: diagnostic and treatment devices for swallowing problems, and nutritional food products tailored to a patient's diagnosed level of swallowing difficulty. | $1.4M / Dec 03, 2013 | |
| See all 17 investments → | |||
Co-Investors
Wisconsin Investment Partners
14 deals together
Venture Management
6 deals together
DSM Venturing
2 deals together
Peak Ridge Capital
2 deals together
Wisconsin Super Angel Fund
2 deals together
BrightStar Wisconsin Foundation
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
Health Care Investors
43,014 investors
Biotech Investors
21,775 investors
Biotechnology Investors
19,370 investors
Medical Investors
18,848 investors
Life Science Investors
6,823 investors
Health Care VC Funds
32,370 investors
Biotech VC Funds
18,864 investors
Biotechnology VC Funds
17,016 investors
Medical VC Funds
16,214 investors
FAQ
What does NEW Capital Fund invest in?
NEW Capital Fund invests primarily in Biotechnology, Medical and Health Care startups, most often at Funding Round and Debt Financing stage. Most of the 17 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact NEW Capital Fund?
Public channels for NEW Capital Fund include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at NEW Capital Fund?
The team at NEW Capital Fund includes Charlie Goff (Accounts), David Gitter (MD) and Robert DeBruin (President). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
